0001140361-16-053439.txt : 20160217 0001140361-16-053439.hdr.sgml : 20160217 20160216173633 ACCESSION NUMBER: 0001140361-16-053439 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160217 DATE AS OF CHANGE: 20160216 EFFECTIVENESS DATE: 20160217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chase Pharmaceuticals Corp CENTRAL INDEX KEY: 0001509008 IRS NUMBER: 208866868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-246193 FILM NUMBER: 161430612 BUSINESS ADDRESS: STREET 1: 1823 K STREET, NW STREET 2: SUITE 520 CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 202-223-7002 MAIL ADDRESS: STREET 1: 1823 K STREET, NW STREET 2: SUITE 520 CITY: WASHINGTON STATE: DC ZIP: 20006 D/A 1 primary_doc.xml X0707 D/A LIVE 0001509008 Chase Pharmaceuticals Corp 1825 K Street, NW Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 202-792-4621 DELAWARE None None Corporation true Douglas Ingram c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Thomas N. Chase c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Executive Officer Director Kathleen Clarence-Smith c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Executive Officer Stephen Cunningham c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Karoly Nikolich c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Nayan Greg Parekh c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director John M. Reher c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Executive Officer Vikram Sudarsan c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Raphael Wisniewski c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Pharmaceuticals Decline to Disclose 06b true 0001140361-15-032968 2015-08-05 false true true true false 0 3500000 3500000 0 This filing covers the sale and issuance of Series B-1A Preferred Stock, the Common Stock issuable upon conversion thereof and the sale and issuance of Warrants exercisable for Series B-1A Preferred Stock and the stock issuable upon conversion thereof. false 13 0 0 0 false Chase Pharmaceuticals Corp /s/ Douglas Ingram Douglas Ingram Chief Executive Officer 2016-02-16